CN106008569B9 - 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途 - Google Patents

作为精氨酸酶抑制剂的硼酸盐及其组合物和用途 Download PDF

Info

Publication number
CN106008569B9
CN106008569B9 CN201610322649.4A CN201610322649A CN106008569B9 CN 106008569 B9 CN106008569 B9 CN 106008569B9 CN 201610322649 A CN201610322649 A CN 201610322649A CN 106008569 B9 CN106008569 B9 CN 106008569B9
Authority
CN
China
Prior art keywords
aryl
alkyl
alkylene
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610322649.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106008569A (zh
CN106008569B (zh
Inventor
迈克尔·范赞特
甘纳尔·艾瑞克·小亚格德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of CN106008569A publication Critical patent/CN106008569A/zh
Publication of CN106008569B publication Critical patent/CN106008569B/zh
Application granted granted Critical
Publication of CN106008569B9 publication Critical patent/CN106008569B9/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201610322649.4A 2010-10-26 2011-10-19 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途 Expired - Fee Related CN106008569B9 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40676010P 2010-10-26 2010-10-26
US61/406,760 2010-10-26
CN201180057717.4A CN103249737B (zh) 2010-10-26 2011-10-19 作为精氨酸酶抑制剂的硼酸盐

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180057717.4A Division CN103249737B (zh) 2010-10-26 2011-10-19 作为精氨酸酶抑制剂的硼酸盐

Publications (3)

Publication Number Publication Date
CN106008569A CN106008569A (zh) 2016-10-12
CN106008569B CN106008569B (zh) 2020-04-03
CN106008569B9 true CN106008569B9 (zh) 2020-05-22

Family

ID=44913403

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610322649.4A Expired - Fee Related CN106008569B9 (zh) 2010-10-26 2011-10-19 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途
CN201180057717.4A Expired - Fee Related CN103249737B (zh) 2010-10-26 2011-10-19 作为精氨酸酶抑制剂的硼酸盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180057717.4A Expired - Fee Related CN103249737B (zh) 2010-10-26 2011-10-19 作为精氨酸酶抑制剂的硼酸盐

Country Status (19)

Country Link
US (5) US9233985B2 (enExample)
EP (3) EP3719024A1 (enExample)
JP (1) JP5909239B2 (enExample)
CN (2) CN106008569B9 (enExample)
AU (1) AU2011320732B2 (enExample)
BR (1) BR112013010099B1 (enExample)
CA (1) CA2815536C (enExample)
DK (1) DK2632927T3 (enExample)
ES (2) ES2568680T3 (enExample)
HK (1) HK1223104A1 (enExample)
HR (1) HRP20160305T1 (enExample)
HU (1) HUE027317T2 (enExample)
IL (1) IL225926A (enExample)
MX (1) MX336381B (enExample)
PL (1) PL2632927T3 (enExample)
RS (1) RS54750B1 (enExample)
SI (1) SI2632927T1 (enExample)
SM (1) SMT201600141B (enExample)
WO (1) WO2012058065A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
HUE048859T2 (hu) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
WO2013158262A1 (en) * 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2944903A1 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
EA201691988A1 (ru) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX385315B (es) * 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
CN108368176B (zh) 2015-10-01 2022-06-07 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
TWI710565B (zh) * 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
CA3042878A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
MX378460B (es) * 2016-12-22 2025-03-10 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad de la arginasa.
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
BR112019023582A2 (pt) 2017-05-12 2020-06-02 Calithera Biosciences Inc. Método de preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CA3091365A1 (en) 2018-02-17 2019-08-22 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EA202092086A1 (ru) * 2018-03-05 2021-02-09 Аркус Байосайенсиз, Инк. Ингибиторы аргиназы
WO2019177873A1 (en) * 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
PL3774843T3 (pl) 2018-03-29 2022-11-14 Molecure Sa Dipeptydowe pochodne piperydyny
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN111770756B (zh) * 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
AU2019379808C1 (en) * 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020131598A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
IL285108B2 (en) 2019-02-08 2024-10-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof
JP7579324B2 (ja) * 2019-07-23 2024-11-07 アストラゼネカ・アクチエボラーグ アルギナーゼ阻害剤及びその使用方法
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SI4175719T1 (sl) 2020-07-02 2025-07-31 Incyte Corporation Triciklične sečninske spojine kot zaviralci jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
WO2023283332A1 (en) * 2021-07-07 2023-01-12 Emory University Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
WO2023191116A2 (en) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Improved suramin methods and compositions
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202416968A (zh) 2022-10-21 2024-05-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
CN121079299A (zh) 2023-03-13 2025-12-05 因赛特公司 作为激酶抑制剂的双环脲

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249737B (zh) * 2010-10-26 2016-06-08 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009890A (en) 1911-02-09 1911-11-28 Michael F Brauer Dumping attachment for headers.
US1006597A (en) 1911-05-26 1911-10-24 Rail Joint Co Insulated rail-joint.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6403609B1 (en) 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
EP1049660A1 (en) * 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
WO2002004465A1 (en) 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
MX2009005370A (es) 2006-11-21 2009-10-16 Univ Groningen Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica.
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
KR20100080798A (ko) 2007-10-12 2010-07-12 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
HUE046932T2 (hu) 2009-01-26 2020-04-28 Univ Pennsylvania Argináz inhibitorok és felhasználási eljárások
AU2011242794B2 (en) * 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
BR112014009531A8 (pt) 2011-10-20 2018-01-16 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
CN111329989A (zh) 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EP3270907A1 (en) 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
MX385315B (es) 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX378460B (es) 2016-12-22 2025-03-10 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad de la arginasa.
BR112019023582A2 (pt) 2017-05-12 2020-06-02 Calithera Biosciences Inc. Método de preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249737B (zh) * 2010-10-26 2016-06-08 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Classical and Slow-Binding Inhibitors of Humman Type II Arginase;David E. Ash et al.;《Biochemistry》;20010707;第40卷;第213-219页 *
Synthesis of a series of boronated unnatural cyclic amino acids as potential boron neutron capture therapy agents;George W. Kabalka et al.;《Apllied Organometallic Chemistry》;20081231;第22卷;第517页图1 *
有机硼酸类酶抑制剂的研究进展;李磊 等;《中国医药工业杂志》;20090310;第40卷(第3期);第9356-9362页 *

Also Published As

Publication number Publication date
IL225926A0 (en) 2013-06-27
CA2815536A1 (en) 2012-05-03
ES2568680T3 (es) 2016-05-03
EP2632927A1 (en) 2013-09-04
CN106008569A (zh) 2016-10-12
SI2632927T1 (sl) 2016-08-31
EP2632927B1 (en) 2016-02-10
CN103249737B (zh) 2016-06-08
HRP20160305T1 (hr) 2016-07-01
SMT201600141B (it) 2016-07-01
DK2632927T3 (en) 2016-04-11
MX2013004491A (es) 2013-11-04
EP3034509A1 (en) 2016-06-22
IL225926A (en) 2016-09-29
BR112013010099B1 (pt) 2021-08-10
HK1223104A1 (en) 2017-07-21
HK1225390A1 (zh) 2017-09-08
PL2632927T3 (pl) 2016-09-30
US9440995B2 (en) 2016-09-13
JP5909239B2 (ja) 2016-04-26
JP2013542223A (ja) 2013-11-21
HUE027317T2 (en) 2016-10-28
AU2011320732A1 (en) 2013-11-21
US10098902B2 (en) 2018-10-16
CN103249737A (zh) 2013-08-14
BR112013010099A2 (pt) 2016-09-06
WO2012058065A1 (en) 2012-05-03
EP3719024A1 (en) 2020-10-07
CA2815536C (en) 2019-10-01
US20190054101A1 (en) 2019-02-21
CN106008569B (zh) 2020-04-03
US20150191492A1 (en) 2015-07-09
MX336381B (es) 2016-01-18
ES2794006T3 (es) 2020-11-17
US20200246362A1 (en) 2020-08-06
US11389464B2 (en) 2022-07-19
US20120129806A1 (en) 2012-05-24
EP3034509B1 (en) 2020-04-22
RS54750B1 (sr) 2016-10-31
US10603330B2 (en) 2020-03-31
US9233985B2 (en) 2016-01-12
US20170000808A1 (en) 2017-01-05
AU2011320732B2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
CN106008569B9 (zh) 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途
CN104876955B (zh) 精氨酸酶抑制剂及其治疗应用
HK1225390B (zh) 作为精氨酸酶抑制剂的硼酸盐及其组合物和用途
HK1213901B (zh) 精氨酸酶抑制剂及其治疗应用
HK1203853B (en) Inhibitors of arginase and their therapeutic applications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225390

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CI03 Correction of invention patent

Correction item: Claims

Correct: Correct

False: error

Number: 14-02

Page: full text

Volume: 36

CI03 Correction of invention patent
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200403

CF01 Termination of patent right due to non-payment of annual fee